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There are two subtypes of hepatitis B virus genotype A (HBV/A) and they are provisionally
designated Aa (“a” standing for Africa/Asia) and Ae (“e” for Europe). In a case-control study, 78
HBV/Aa, 78HBV/Ae, and 78HBV/D carriers from several countries were compared. The prev-
alence of HBe antigen (HBeAg) in serum was significantly lower in carriers of HBV/Aa than in
carriers ofHBV/Ae (31% vs. 49%;P .033), with a differencemore obvious in the carriers aged
30 years or younger (34% vs. 67%; P  .029). HBV DNA levels in the carriers of HBV/Aa
(median, 3.46 log copies/mL; 95%CI, 2.93–3.95) were significantly lower than those of carriers
of HBV/Ae (6.09 log copies/mL; 95% CI, 4.24–7.64) or of carriers of HBV/D (5.48 log copies/
mL; 95% CI, 4.06–7.02), regardless of the HBeAg status (P < .001). The most specific and
frequent substitutions in 54 HBV/Aa isolates were double substitutions for T1809 (100%) and
T1812 (96%) immediately upstream of the precore initiation codon, whichwould interfere with
the translation of HBeAg in HBV/Aa infections. They were not detected in 57 HBV/Ae or 61
HBV/D isolates examined. The doublemutation in the core promoter (T1762/A1764)wasmore
frequent in both HBV/Aa (50%) and HBV/Ae (44%) than in HBV/D isolates (25%; P< .01),
whereas the precore mutation (A1896) occurred in HBV/D isolates only (48%; P< .0001). In
conclusion, the clearance ofHBeAg from serummay occur by differentmechanisms inHBV/Aa,
HBV/Ae, and HBV/D infections, which may influence clinical manifestations in the Western
countries where both genotypes A and D are prevalent. (HEPATOLOGY 2004;40:747–755.)
Seven major genotypes of hepatitis B virus (HBV)have been classified by a sequence divergence inthe entire genome in excess of 8%, and they are
named by capital alphabet letters from A through G.1–3
An eighth genotype is proposed under the designation
H,4 but its independence from genotype F has yet to be
verified by strict phylogenetic analyses. HBV geno-
types have distinct geographical distributions.5,6 Thus,
genotype A (HBV/A) is predominant in Europe and
Africa; HBV/B and HBV/C are prevalent in East and
South Asia; HBV/D is common in the Mediterranean
area, the Middle East, and India; HBV/E is restricted
to sub-Saharan Africa; and HBV/F is localized in the
Central and South America. All seven genotypes occur
in the United States with frequencies dependent on the
ethnicity.7 More recently, HBV/G was found in
France, Germany, and the United States,3,7,8 and al-
ways coinfects hosts with genotype A.3,9
There have been increasing lines of evidence to indicate in-
fluences ofHBVgenotypes on the outcome of liver disease and
the response to antiviral therapies, especially between genotypes
BandC, common inAsia.10–13 Evidence for clinical differences
between genotype A andD infections is scarce.14,15
Abbreviations: HBV, hepatitis B virus; nt, nucleotide; HBeAg, hepatitis B e
antigen; HCC, hepatocellular carcinoma; anti-HBe, antibody to hepatitis B e an-
tigen; PCR, polymerase chain reaction; ALT, alanine aminotransferase.
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HBV isolates even of the same genotype may differ
both virologically and clinically. Two subtypes of geno-
type B in distinct geographical distributions, designated
Ba (“a” standing for Asia) and Bj (“j” for Japan) provision-
ally,16 and clinical differences between patients infected
with HBV/Ba andHBV/Bj are coming to the fore.17,18 In
a phylogenetic analysis of the pre-S2/S region, Bowyer et
al.19 found that African HBV/A isolates cluster on a
branch separate from the original genotype A from Eu-
rope and reported it under the designation subgroup A.
Their findings have been extended, by comparison of the
entire nucleotide (nt) sequences of many HBV/A isolates,
leading to the proposal of two subtypes or subgenotypes
of genotype A.20–22 The one subtype of genotype A orig-
inally reported and distributed widely in European coun-
tries and the United States was tentatively designated
subtype Ae (“e” standing for Europe), whereas the other
prevailing in sub-Saharan Africa,21,23 corresponding to
subgroup A of Bowyer et al.19 and also found in Asia,20
was provisionally named subtype Aa (“a” for Africa/Asia).
There have been some lines of evidence for virological and
clinical differences between subtypeAa inAfrica and subtype
Ae in Europe and the United States. Infection with subtype
Aa is associated with low serum levels of HBVDNA as well
as low prevalence of hepatitis B e antigen (HBeAg) in serum
and is implicated in the high incidence of HBV-induced
hepatocellular carcinoma (HCC) in Africa.24,25 In 1999,
Baptista et al.26 reported the presence of nucleotide substitu-
tions within the Kozak sequence, immediately upstream of
the initiation codon of the precore region that were shown
subsequently to interfere with the translation ofHBeAg pre-
cursor.27 These mutations are found exclusively in subtype
Aa isolates and probably contribute to the early loss of
HBeAg from serum in the individuals infectedwith this sub-
type in Africa.28,29
For the purpose of determining clinical and virological
differences between subtypes Aa and Ae infections, in com-
parison with genotype D infection prevalent along with ge-
notype A in theWestern countries, a case-control study was
performed of 234 carriers from several countries who were
infected with one of the two subtypes of genotype A (Aa and
Ae) or genotypeD (78 in each group). Sequence analyses for
mutations affecting the synthesis of HBeAg on HBV DNA
from these patients suggest distinct mechanisms for the loss
of HBeAg from serum that could affect clinical outcomes of
patients infected with one of the two subtypes of genotype A
or genotype D.
Patients and Methods
Serum Samples. Sera were obtained from 234 pa-
tients infected with subtype Aa (78 patients) or Ae (78
patients) of genotype A or with genotype D (78 patients)
from several countries who were controlled for sex, age,
and severity of liver disease: nine were from Bangladesh,
84 from India, 29 from Japan, 7 from Nepal, 14 from
South Africa, 10 from Tanzania, and 81 from the United
States. None were positive for serological markers of in-
fection with hepatitis C virus or human immunodefi-
ciency virus type 1. HBVDNA sequences were examined
for mutations affecting the synthesis of HBeAg, and the
results were correlated withHBeAg andHBVDNA levels
in serum, as well as subtypes of genotype A (Aa and Ae)
and genotype D. The study protocol was approved by
ethics committees of the institutions in accordance with
the 1975 Declaration in Helsinki, and an informed con-
sent was obtained from each patient.
Serological Assays for HBV Markers. HBeAg was
detected by Chemiluminescent enzyme immunoassay
(Ortho Clinical Diagnostics, Tokyo, Japan). The seven
major HBV genotypes (A–G) were determined by en-
zyme-linked immunosorbent assay with monoclonal an-
tibodies directed to distinct epitopes on the preS2-region
products,30 with use of commercial kits (HBV GENO-
TYPE EIA; Institute of Immunology Co., Ltd., Tokyo,
Japan) used for genotypes other than G. The genotype G
was determined by the combination of preS2 serotype for
genotype D and serotype adw of HBsAg; it is characteris-
tic of this genotype.9
Detection and Quantification of Serum HBV DNA.
HBV DNA sequences spanning the S gene were deter-
mined by real-time detection polymerase chain reaction
(PCR) according to the method of Abe et al.31 with a
forward primer (HBSF2: 5-CTTCATCCTGCTGCT
ATG CCT-3 [nt 406–426]), a reverse primer (HBSR2:
5-AAA GCC CAG GAT GAT GGG AT-3 [nt 646–
627]), and Taq Man probe HBSP2 (5-ATG TTG CCC
GTT TGT CCT CTA ATT CCA G-3 [nt 461–488]),
with an additional G at the 3-end of HBSP2 in the orig-
inal method. The detection limit of this study was 100
copies/mL.
PCR-Restriction Fragment Length Polymorphism
for Confirmation of Genotype A and Determination
of Subtype Ae. Nucleic acids were extracted from 100
L of serum using QIAamp DNA Blood Mini Kit (Qia-
gen Inc., Hilden, Germany). A novel method for confir-
mation of genotype A and specific determination of
HBV/Ae consisted of two PCR cycles with heminested
primers followed by restriction fragment length polymor-
phismwith the restriction site specific for HBV/Ae.32 The
first-round PCR was performed with a sense primer
(HB7F: 5-GAGACCACCGTGAACGCCCA -3 [nt
1611–1630]) and an antisense primer (HB7R-2: 5-CCT
GAG TGC TGT ATG GTG AGG-3 [nt 2072–2052])
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in a 96-well cycler. The second-round PCR was per-
formed twice separately with different sets of primers. Set
I was used for confirmation of genotype A and was com-
posed of a sense primer (HBxA: 5-ATT GGT CTG
CGCACCA-3 [nt 1793–1808]) deduced from the con-
served regions of the X gene and an antisense primer
(HB7R-2), and set II was comprised of a sense primer
(HBxAe: 5-ATT GGT CTG CGC ACC AGG AC-3
[nt 1793–1812]) bearing sequences specific for HBV/Ae
at the 3-end and an antisense primer (HB7R-2). For
coping with occasional atypical isolates, amplification
products were tested by restriction fragment length poly-
morphism for the restriction site of BglII that is possessed
by HBV/Ae but not HBV/Aa sequences. Amplicons by
PCR with set II of 282 base pairs were digested with 10 U
BglII (New England BioLabs, Beverly, MA). The digest
was run by electrophoresis on 3% (wt/vol) agarose, was
stained with ethidium bromide, and was observed in ul-
traviolet light. Amplification products on HBV/Ae iso-
lates gave rise to two fragments of 221 and 61 base pairs,
respectively, whereas those on HBV/Aa isolates did not.
Amplification and Sequencing of the Core Pro-
moter as Well as the Precore Region Plus Core Gene.
HBVDNA sequences bearing the core promoter and pre-
core or core regions were amplified by PCR with hemin-
ested primers by the method described previously.33
Thereafter, PCR products were sequenced directly with
Prism Big Dye (Applied Biosystems, Foster City, CA) in
the ABI 3100 DNA automated sequencer (Applied Bio-
systems).
Molecular Evolutionary Analyses of HBV. Refer-
ence sequences were retrieved from the DDBJ/EMBL/
GenBank database along with their accession numbers for
identification. Nucleotide sequences of HBV were
aligned by the program CLUSTAL X, and the genetic
distance was estimated with the six-parameter method34
in the Hepatitis Virus Database.35 Based on these values,
a phylogenetic tree was constructed by the neighbor-join-
ing method with the midpoint rooting option. To con-
firm the reliability of the phylogenetic tree, bootstrap
resampling tests were performed 1,000 times.
A Case-Control Study for Clinical and Virological
Differences Among HBV/Aa, HBV/Ae, and HBV/D
Infections. Clinical and serological data were available
for the 78 individuals persistently infected with HBV/Aa
(9 from Bangladesh, 29 from India, 3 from Japan, 7 from
Nepal, 6 from the United States, 14 from South Africa,
and 10 from Tanzania). Serving as controls were 78 car-
riers of HBV/Ae and 78 carriers of HBV/D randomly
recruited from India (none and 55 carriers, respectively),
Japan (26 and none, respectively), and the United States
(52 and 23); they were matched for mean age and gender
with the 78 carriers of HBV/Aa. They also were matched
for the severity of liver disease in each group, including 22
asymptomatic carriers with normal alanine aminotrans-
ferase (ALT) levels and 56 patients with liver disease. An
asymptomatic carrier was defined as a HBsAg-positive
individual with normal ALT levels over 1 year (examined
at least four times at 3-month intervals), without the pres-
ence of portal hypertension. Chronic hepatitis was de-
fined as persistent elevation of ALT levels (1.5 upper
limit of normal [35 U/L]) over a 6-month period (at least
three readings at 2-month intervals), accompanied by his-
tological documentation of grading and staging scores.36
Cirrhosis was determined mainly by ultrasonography
(coarse liver architecture, nodular liver surface, and blunt
liver edges) and evidence of hypersplenism (splenomegaly
on ultrasonography), a platelet count100,000/mm3, or
a combination thereof. Confirmation by fine-needle bi-
opsy of the liver was performed as required. Available
histological results among the studied chronic hepatitis
patients indicated no significant differences amongHBV/
Aa, HBV/Ae, and HBV/D groups: 0.93 0.53, 1.19
0.84, 0.88  0.78 in grades, respectively, and 1.38 
0.81, 1.22  0.90, 1.48  1.01 in stages. None had
received antiviral treatment during the follow-up period.
Statistical Analysis. Statistical differences were eval-
uated by the Mann-Whitney U test, Fisher exact proba-
bility test, and chi-square test with Yates’s correction,
where appropriate, with use of STATA software, version
8.0 (StataCorp. LP, College Station, TX). Differences
were considered significant for P values less than .05.
Results
Phylogenetic Relatedness of the Two Subtypes of
HBV/A and HBV/D. For further characterization of
HBV genotypes in the 234 carriers participating in a case-
control study, 54 (69%) HBV/Aa, 57 (73%) HBV/Ae, and
61 (78%) HBV/D isolates could be amplified and were se-
quenced over the core promoter and precore or core regions
spanning398basepairs.The remaining62 isolates couldnot
be sequenced over the target because of their lowHBVDNA
levels in serum. Together with 14 HBV/A and HBV/D se-
quences retrieved from the database, the 54HBV/Aa and 57
HBV/Ae isolates sequenced in the present study were sub-
jected to a phylogenetic analysis along with the six sequences
representative of subtypes Ba andBj of genotype B, as well as
genotypes C, E, F, and G, respectively (Fig. 1). The 54
HBV/Aa isolates in the present study, including 4 fromBan-
gladesh, 21 from India, 3 from Japan, 7 fromNepal, 9 from
SouthAfrica, 7 fromTanzania, and 3 from theUnited States
clustered with the HBV/Aa isolates from India, Malawi,
Philippines, and SouthAfrica retrieved from the database; all
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three U.S. patients were Asians from the Philippines. Al-
though their sequences diverged widely, no clusterings were
indigenous to any countries of origin. In contrast, the 57
HBV/Ae isolates, including 14 from Japan and 43 from the
United States, had less sequence divergence and clustered
closelywith theHBV/Ae isolates from theWestern countries
and Japan retrieved from the database. Thus, the mean ge-
netic distance in the target sequence amongHBV/Aa isolates
was significantly greater than that among HBV/Ae isolates
(0.0279 0.0045 vs. 0.0098 0.0017; P .01), thereby
suggesting thatHBV/Aa would be of amuch older phyloge-
netic origin and have infiltrated into the world more deeply
than HBV/Ae. There were no differences in the HBeAg
status between carriers of HBV/Aa and HBV/Ae from
whom they were recovered (24/54 [44%] vs. 30/57 [53%]).
The 61 HBV/D isolates, including 49 from India and 12
from the United States, clustered with the HBV/D isolates
from the Western countries and India.
Serum HBeAg in Patients Infected With HBV/Aa,
HBV/Ae, or HBV/D. Table 1 compares the HBeAg sta-
tus and HBVDNA levels, as well as mutations in the core
promoter and precore region, among 78 each carriers of
HBV/Aa, HBV/Ae, or HBV/D in a case-control study.
There were no significant differences in ALT levels among
the patients, because they were equalized for the severity
of liver disease. The prevalence of HBeAg was signifi-
cantly lower in the carriers of HBV/Aa than in the carriers
of HBV/Ae (24/78 [31%] vs. 38/78 [49%]; P  .033),
although there were no significant differences between
HBV/A (HBV/Aa or HBV/Ae) and HBV/D infections.
Figure 2 depicts the prevalence of HBeAg in carriers of
HBV/Aa, HBV/Ae, or HBV/D stratified by the age. The
prevalence of HBeAg tended to decrease with age in all
carriers, regardless of HBV genotypes. HBeAg was signif-
icantly less frequent in carriers of HBV/Aa than in carriers
of HBV/Ae who were aged 30 years or younger (11/32
[34%] vs. 16/24 [67%]; P  .029).
HBV DNA Levels in Patients Infected With HBV/
Aa, HBV/Ae, or HBV/D, with or Without Serum
HBeAg. In the patients with HBeAg in serum, HBV
DNA levels were significantly lower in those infected with
HBV/Aa (median, 5.49 log copies/mL; 95% CI, 4.64–
6.79]) than in those infected withHBV/Ae (median, 8.36
log copies/mL; 95%CI, 7.62–8.67) or HBV/D (8.57 log
copies/mL; 95% CI, 7.73–8.91; P  .0001; Fig. 3). In
the HBeAg-negative patients, HBV DNA levels were sig-
nificantly lower in those carrying HBV/Aa (2.74 log cop-
ies/mL; 95% CI, 2.05–3.32) than in those carrying
HBV/Ae (3.60 log copies/mL; 2.90–4.46; P  .0031)
and those carryingHBV/D (3.63 log copies/mL; 95%CI,
3.12–4.13; P  .034; Fig. 3).
Mutations in the Core Promoter and Precore Re-
gion in Patients Infected With HBV/Aa, HBV/Ae, or
HBV/D. An alignment of sequences covering the basic
core promoter and the encapsidation signal () in HBV of
distinct genotypes or subtypes allowed the identification
Fig. 1. A phylogenetic tree constructed on the X gene, precore region
and core gene sequences. Together with 14 sequences of hepatitis B
virus genotype A (HBV/A) and hepatitis B virus genotype D (HBV/D)
isolates retrieved from the database, the 111 HBV/A sequences deter-
mined in the present study were subjected to phylogenetic analyses
along with six HBV isolates representative of genotypes Ba, Bj, C, E, F,
and G, respectively. Isolates sequenced in the present study are shown
with the country of origin in abbreviation for Bangladesh (BAN), India
(IND), Japan (JPN), Nepal (NEP), South Africa (SAF), Tanzania (TAN), and
the United States (USA). Reference isolates from the database are
identified with accession numbers. The numbers on nodes indicate
bootstrap reliability (1,000). Plus and minus signs at the end of
isolates represent positive and negative hepatitis B e antigen in serum of
carriers from whom HBV isolates were recovered.
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of specific substitutions in HBV/Aa isolates, namely
T1809, T1812, T1862, and H1888 (H representing
non-G; Fig. 4A), which were not present inHBV/Ae (Fig.
4B) or HBV/D isolates (data not shown). T1809 and
T1812 prevailed in HBV/Aa isolates (54/54 [100%] and
52/54 [96%], respectively), but were not detected in any
HBV/Ae or HBV/D isolates. Triple nucleotide substitu-
tions at positions 1809, 1811, and 1812 were detected in
12 HBV/Aa isolates recovered from carriers negative for
serum HBeAg. Remarkably, the point mutations within
, G to T at nt 1862 and G to A, C, or T at nt 1888,
occurred frequently in HBV/Aa isolates (40/54 [74%]
and 42/54 [78%], respectively) but were not seen in any
HBV/Ae (0/57) or HBV/D isolates (0/61).
The precore stopmutation (A1896), accompanied by a
C-to-T mutation at nt 1858 forming a base pair with it,
was not found in HBV/Aa isolates, whereas another pre-
Table 1. Demographic, Clinical and Virological Characteristics of Patients Infected with HBV of Genotype Aa, Ae, or D
Features
HBV Genotypes
Differences
P ValueAa (n  78) Ae (n  78) D (n  78)
Men 65 (83%) 65 (83%) 65 (83%) Matched
Age (yr) 37.9 14.0 39.1 12.6 37.6 12.6 Matched
Clinical status
Asymptomatic 22 (28%) 22 (28%) 22 (28%) Matched
Liver disease 56 (72%) 56 (72%) 56 (72%) Matched
Cirrhosis (HCC) 24 (5) 25 (2) 26 (8)
ALT (IU/L) 36 (26–43) 36 (29–62) 36 (32–46) NS
HBeAg 24 (31%) 38 (49%) 29 (37%) .033†
HBV DNA (log copies/mL) 3.46* 6.09 5.48 .001
95% Cl (2.93–3.95) (4.24–7.64) (4.06–7.02)
Mutations in the core promoter
T1762/A1764 27/54 (50%) 25/57 (44%) 15/61 (25%)* .01
Mutations in the ATG initiator codon in the precore region
T1809 54/54 (100%)* 0/50 (0%) 0/61 (0%) .0001
T1812 52/54 (96%)* 0/57 (0%) 0/61 (0%) .0001
Mutations in the precore region
T1858 0/54 (0%) 0/57 (0%) 61/61 (100%)* .0001
T1862 40/54 (74%)* 0/57 (0%) 0/61 (0%) .0001
H1888 42/54 (78%)* 0/57 (0%) 0/61 (0%) .0001
A1896 0/54 (0%) 0/57 (0%) 29/61 (48%)* .0001
Note. Median values and 95% confidence intervals in parentheses are shown for ALT and HBV DNA.
*Significantly different from the other genotypes.
†Significantly different between Aa and Ae.
Fig. 2. Age-specific prevalence rates of hepatitis B e antigen (HbeAg)
in carriers of hepatitis B virus genotype Aa (HBV/Aa), hepatitis B virus
genotype Ae (HBV/Ae), or hepatitis B virus genotype D (HBV/D).
Fig. 3. Hepatitis B virus (HBV) DNA levels in carriers of hepatitis B
virus genotype Aa (HBV/Aa), hepatitis B virus genotype Ae (HBV/Ae),
and hepatitis B virus genotype D (HBV/D) with or without hepatitis B e
antigen (HBeAg) in serum. HBV DNA was quantitated by real-time
detection polymerase chain reaction, and the results are shown in log
copies per milliliter. The box indicates 75 (upper edge), 50 (in between
[median]), and 25 (lower edge) percentiles and bars indicate 90 and 10
percentiles, respectively.
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core stop mutation (A1897), accompanied by a C-to-T
mutation at nt 1857, was found in two HBV/Ae isolates
from HBeAg-negative carriers in the United States (Fig.
4B). The double mutation in the basic core promoter
(T1762/A1764) was found significantly less often in car-
riers of HBV/D than in carriers of HBV/Aa (25% vs.
50%; P .0065) or HBV/Ae (25% vs. 44%; P .033),
with remarkably more mutations in carriers of HBV/Aa
(Table 1). Figure 5 compares the frequency of core pro-
moter and precore mutations between carriers of HBV/
Aa, HBV/Ae, or HBV/D with and without HBeAg in the
serum. The basic core promoter double mutation was
significantly more frequent in HBV/Ae carriers without
than with HBeAg (63% vs. 27%; P  .013). In sharp
contrast, the HBeAg status did not influence the fre-
quency of these mutations in HBV/Aa carriers. In
HBV/D carriers, both core promoter and precore stop
mutations were significantly more common in those
without than with HBeAg (36% vs. 11%; P .035; and
67% vs. 25%; P  .0019, respectively).
Fig. 4. Nucleotide sequences spanning the basic core promoter and pregenome encapsidation signal in hepatitis B virus (HBV) isolates of (A)
subtype Aa and (B) subtype Ae. Positions of the double mutation (nucleotide [nt] 1762 and 1764), two substitutions frequent in subtype Aa (nt 1809
and 1812), and C1858 making a pair with G1896, as well as those of mutations at nt 1862 and nt 1888 specific for subtype Aa are indicated by
inverted triangles. The ATG initiation codon of the precore region is shaded. The reference sequence is shown for the AF090839Ae of subtype Ae
at the top. HBeAg, hepatitis B e antigen; , positive; –, negative; BAN, Bangladesh; IND, India; JPN, Japan; NEP, Nepal; SAF, South Africa; TAN,
Tanzania; USA, United States.
Fig. 5. The frequency of basic core promoter (BCP) mutation (T1762/
A1764) and precore mutation (A1896) among carriers of hepatitis B
virus genotype Aa (HBV/Aa), hepatitis B virus genotype Ae (HBV/Ae),
and hepatitis B virus genotype D (HBV/D) with or without serum hepatitis
B e antigen (HBeAg). The prevalence of BCP mutation in HBV/Ae isolates
from carriers without HBeAg was significantly higher than that from those
with HBeAg (63% vs. 27%; P  .013). The prevalence of BCP or precore
mutation in HBV/D isolates from carriers without HBeAg was significantly
higher than that from those with HBeAg (36% vs. 11%; P .035; or 67%
vs. 25%; P  .0019). , positive; –, negative.
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Discussion
In the present case-control study, the prevalence of
HBeAg was found to be significantly lower in the carriers
of HBV/Aa than in carriers of HBV/Ae. This is consistent
with the observation that Africans infected with HBV
frequently lose HBeAg from serum in infancy or early
childhood,28,29 in contrast to inhabitants of other coun-
tries where HBV is endemic, who lose HBeAg later in
life.37–39 Moreover, subtype Aa, first reported in 1997 as
subgroup A by Bowyer et al.,19 is the major genotype of
HBV in southern Africa19,21,22 and is common in young
patients with HCC in South Africa (Kew MC et al., sub-
mitted for publication, 2004).40 These findings suggest
that HBV/Aa in Africa is distinct fromHBV/Ae inWest-
ern countries20–22 and is associated with HCC in young
ages (Kew MC et al., submitted for publication, 2004).
HBV/Aa isolates have been reported to have distinctive
sequence characteristics in the basic core promoter and
precore or core regions that could affect HBeAg expres-
sion at different levels.20,21 In this study, the double mu-
tation in the core promoter (T1762/A1764) that has been
shown to affect transcription41 was found significantly
more frequently in HBV/Ae isolates without than with
HBeAg, suggesting that it would be associated with
HBeAg clearance in HBV/Ae carriers (Fig. 5). However,
although T1762/A1764 was highly prevalent in isolates
from carriers of HBV/Aa, it did not associate with the
HBeAg status. This is in agreement with the results of a
previous study that also showed a high prevalence of these
mutations in HCC patients compared with asymptom-
atic carriers (66% vs. 11%).26 Furthermore, the classic
precore stop codon mutation (A1896) was detected more
often in HBV/D than in HBV/Aa or HBV/Ae isolates.
At the level of translation, double nucleotide substitu-
tions at nt 1809 and 1812 immediately upstream of the
precore ATG initiation codon, 5-TCATCATGC-3
(precore start codon underlined and double substitutions
in italics), and occasional triple nucleotide substitutions
with an additional mutation at nt 1811 were described by
Baptista et al.26 and Ahn et al.27 Using elegant expression
studies, Ahn et al.27 demonstrated that an adenosine or
guanine, at the 3 position with reference to the ATG
start codon, affected the translation efficiency of the
HBeAg precursor by a leaky scanning mechanism,42 pro-
viding an account on the early loss of HBeAg in carriers of
HBV/Aa in Africa.28,29 Notably, these 1809–1812 muta-
tions are highly prevalent in HBV/Aa strains from South
Africans with acute infection, during childhood, and in
the HBeAg-positive phase of infection,27 indicating these
mutations as stable traits of HBV/Aa, rather than as adap-
tive changes under anti-HBe immune pressure. Indeed,
simultaneous substitutions at nt 1809 and 1812 have not
been documented in any HBV isolates other than
HBV/Aa from the database. Inasmuch as carriers harbor
HBV/Aa since infancy in Africa, the process for HBeAg
loss may start from the outset for an early seroconver-
sion.28,29 In outstanding contrast, carriers of HBV/Ae or
HBV/D contract infection with the wild-type with no
mutations, causing loss or downregulation of HBeAg syn-
thesis. Furhtermore, HBV DNA levels in the carriers of
HBV/Aa, who would have a high rate of HBeAg clearance
in young ages,28,29 were significantly lower than those in
the carriers of HBV/Ae or HBV/D, regardless of HBeAg
in serum (Fig. 3). These data indicate a mechanism of
HBeAg seroconversion different between carriers of
HBV/A and HBV/D, or even between carriers with dis-
tinct subtypes of genotype A, Aa, and Ae. Such different
characteristics among carriers of HBV/Aa, HBV/Ae, and
HBV/Dmimic those among subtypes Ba and Bj of geno-
type B and among HBV/C infections in Asian countries.
In our previous case-control study, HBeAg and the dou-
ble mutation in the core promoter were significantly more
frequent in carriers of HBV/C than HBV/B.10 Further-
more, the core promoter mutation was significantly more
frequent in carriers of HBV/Ba than HBV/Bj, in sharp
contrast to the precore stop mutation that was more fre-
quent in carriers ofHBV/Bj than in carriers ofHBV/Ba or
HBV/C.18
Of an additional virological relevance, nt 1862 was
invariably G in all HBV/Ae andHBV/D isolates, whereas
it was T in 40 of the 54 (74%) HBV/Aa isolates. Further-
more, nt 1888 was exclusively G in HBV/Ae isolates, but
it was replaced by A in 36, C in 1, and T in 5, adding up
to 42 of the 54 (78%) HBV/Aa isolates, in confirmation
of earlier reports.20,21,24,25 These two nucleotides are po-
sitioned in the 6-nt bulge and upper stem, respectively,
and make essential elements in the pregenome encapsida-
tion signal. The nt 1862 is G in the wild-type HBV and
occupies the third position in the 6-nt bulge. The conver-
sion of G1862 to any of the other three nucleotides can
affect the replication of HBV43 and can reduce the pro-
duction of HBeAg at the post-translation level in expres-
sion studies in vitro.44
At the protein level, substitutions of nt 1809 and 1812
result in double amino acid replacements in the X protein,
A146S and P147S. The core promoter substitutions at nt
1762 and 1764, which are prevalent in HBV/Aa, also
result in double amino acid changes in the X protein,
K130M and V131I. As the transactivation domain of X
protein is mapped in the carboxyl-terminal portion,45,46
these changes not only may affect the replication of HBV,
but also may play a role in HBV-related hepatocarcino-
genesis as previously proposed.47 Because sub-Saharan Af-
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ricans take the highest dietary aflatoxin B1, which induces
typical G-to-C to T-to-A transversions at the third base in
codon 249 of p53,48 making it, together with HBV, the
major causes of HCC mortality in this geographic area,
further studies are necessary.
In the U.S. population, there was an association be-
tween ethnicity and HBV genotypes. Among 52 U.S.
patients with HBV/Ae, most of them were white persons
born in theUnited States and included one African Amer-
ican, three Hispanics, and two Asians born in the Philip-
pines. However, five of six U.S. carriers with HBV/Aa
were Asians from the Philippines. Among 23 patients
with HBV/D, most were white, some of whomwere born
in Europe, and four were Asians born in India, Afghani-
stan, or Samoa. In agreement with the distribution of
HBV genotypes in association with prevalent HBV geno-
types in the birthplace,7 the present study reinforced a
possible association between ethnicity and subtypes (Aa,
Ae) of HBV/A among U.S. carriers.
In conclusion, specific mutations in HBV/Aa isolates
affect the translation of HBeAg, as well as the replication
of HBV, and may modify clinical outcomes of HBV in-
fections. A prospective study in carriers of HBV/Aa iso-
lates, with and without simultaneous substitutions at nt
1809 and 1812, is required to evaluate the validity of this
hypothesis. Because HBV/Aa strains are different both in
virological characteristics and clinical manifestations
fromHBV/Ae and HBV/D strains, these two subtypes of
HBV/A would need to be distinguished. It is hoped that
the results of this study would encourage research in a
number of epidemiological and clinical settings of West-
ern countries, where genotypes A and D prevail, for eval-
uating clinical outcomes that would be different between
carriers not only of these two genotypes, but also subtypes
Aa and Ae of genotype A.
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